SCHEMBL8529940

SCHEMBL8529940

Cc1cc2ccc(I)cc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.44
KEAP1 Q14145 1/20 0.44
AXL P30530 1/20 0.41
TYMS P04818 1/20 0.37
NOS1 P29475 1/20 0.35
DAO P14920 1/20 0.35
DDO Q99489 1/20 0.35
PTGS2 P35354 1/20 0.35
GAA P10253 3/20 0.34
RXFP1 Q9HBX9 3/20 0.34
KDM4E B2RXH2 3/20 0.34
CYP1A2 P05177 1/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34
MAPT P10636 5/20 0.33
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR3 P22607 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8357705 0.83 CYP2A6 (0.59) CYP2A6KEAP1AXLNOS1PTGS2
SCHEMBL30807019 0.77 DAO (0.55) CYP2A6KEAP1AXLDAODDO
SCHEMBL890079 0.77 DAO (0.55) CYP2A6KEAP1AXLDAODDO
SCHEMBL1438376 0.76 BRD4 (0.59) TYMSDAODDOKDM4ECA12
SCHEMBL2493306 0.74 NOS1 (0.35) NOS1DAODDOMAPTFGFR1
SCHEMBL20101387 0.74 KEAP1 (0.44) CYP2A6KEAP1AXLDAODDO
SCHEMBL475358 0.74 LMNA (0.52) CYP2A6KEAP1AXLNOS1ALDH1A1
SCHEMBL394630 0.74 CYP2A6 (0.70) CYP2A6KEAP1AXLGAARXFP1
SCHEMBL2993745 0.74 KEAP1 (0.52) CYP2A6KEAP1AXLDAODDO
SCHEMBL614723 0.74 LMNA (0.56) CYP2A6KEAP1NOS1DAOGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-02-16 US disclosed
WO-2012083170-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
WO-2012083164-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 EP disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF ROCK1, CYP11B1, CYP4A11 CYP2A6 202/4885KEAP1 921/4885AXL 2402/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 CYP2A6 2579/4885KEAP1 1700/4885AXL 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.